Portal-Bayer Co.Lab Cocktail Reception with ARPA-H and MGB GCTI

​Portal Biotechnologies is excited to be partnering with Bayer Co.Lab for a special cocktail reception with the ARPA-H Investor Catalyst Hub and Massachusetts General Brigham Gene and Cell Therapy Institute (GCTI) on Wednesday, May 22 from 5 - 7PM with doors opening at 4:30PM. Please join Portal Founder and CEO Armon Sharei, Chelsea Schiller, Director, ARPA-H Catalyst Hub, and Roger Hajjar, Director of GCTI, other members of the Cambridge cell and gene therapy innovation community and more!

​Space is limited so make sure you register for your spot soon. Food and drinks will be provided. Please make sure to bring a government ID for entry into the building.

​More about Portal: Portal is an early-stage biotechnology platform company based in Cambridge that has developed a next generation mechanical delivery system for more efficient, cost-effective cell engineering. The technology is compatible with a broad range of cell types and cargoes, thereby enabling new frontiers in cell engineering and analytics. Portal’s early adopters, which include numerous leading academic institutions and pharmaceutical companies, are pursuing applications ranging from clinical-scale cell therapy engineering to novel assays in small molecule drug discovery. For any questions about Portal Biotechnologies, please email Elizabeth Kennedy at elizabeth@portal.bio.